InMed Pharmaceuticals (INM) as of March 31, 2026 presents a deeply distressed liquidation posture with negative recovery to equity under stress assumptions, despite a positive reported book equity of $6.9M. The company has explicitly disclosed substantial doubt about its ability to continue as a going concern within one year of the filing date. Total assets of $9.1M are dominated by cash/equivalents ($5.2M, recoverable at par), intangibles net of $1.5M (zero liquidation value under the lens), PP&E net of $0.6M (recovery ~$0.3-0.4M at 50-70% haircut), and current assets of discontinued operations of $1.1M (mixed quality: $0.35M cash, $0.18M AR, $0.54M inventory). Against these, total liabilities of $2.2M are carried at face. Applying standard liquidation haircuts: cash and equivalents $5.2M (100%), AR of discontinued ops $0.18M (90-95% = ~$0.17M), inventory of discontinued ops $0.54M (60% = ~$0.32M), PP&E $0.64M (60% midpoint = ~$0.38M), intangibles $1.5M (0%), other current assets and prepaids ~$0.62M (uncertain, assume 30-50% = ~$0.25M), short-term investments $0.04M (100%). Gross liquidation proceeds approximately $6.4M against total liabilities of $2.2M at face value yields marginal positive equity recovery of approximately $4.2M — but this excludes contingent liabilities. A material unquantified contingency exists: BayMedica faces arbitration from a licensor seeking approximately $3.4M in past annual minimum payments (2022-2024) plus a declaration of ongoing minimum payments of approximately $2.3M per year for the remainder of the license term. If the licensor prevails, this contingency alone would extinguish any estimated recovery to equity. Additionally, BayMedica's commercial wind-down (board-approved March 4, 2026; target completion June 30, 2026) is expected to incur approximately $550K in severance and $120K in additional wind-down costs. The $531K severance liability is now XBRL-tagged within discontinued operations liabilities (up from zero at June 30, 2025), confirming these are now on-balance-sheet obligations. The company received a Nasdaq minimum bid price deficiency notice on March 27, 2026 (share price below $1.00 for 30 consecutive days), which constrains future equity issuance capacity through the SEPA and other at-the-market facilities. The company has a $124.0M accumulated deficit and is burning approximately $5.7M cash per nine-month period from operations. Management estimates current cash runway into Q4 calendar 2026. The intangible assets ($1.5M net book value, comprising acquired IP and cannabinoid-related patents) are not separately tagged for impairment testing in this filing and carry no liquidation recovery. The Patent License Matter contingency is discussed extensively in MD&A and legal proceedings sections but is not XBRL-tagged as a contingent liability; the absence of a tagged liability for the $3.4M-$5.7M+ potential exposure is itself a disclosure gap worth noting.
▼ Community Notes